Clinical Trial Update: Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK

View source ↗

Summary

Clinical trial update reports the completion of a study examining how variations in albumin levels relate to outcomes in unresectable stage IIIc or stage IV mel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BRAF inhibitor (unspecified) (BRAF inhibitor)
• MEK inhibitor (unspecified) (MEK inhibitor)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Unresecable Stage IIIc or IV Melanoma | Status: COMPLETED